Businesswire  | 
aufrufe Aufrufe: 71

Eurofins Medical Device Services Launches first GMP PFAS Screening and Testing Solutions for Medical Devices

Eurofins Medical Device Services North America, part of a global network of over 20 medical device testing laboratories and a leading medical device solutions partner, recently launcheda GMPPFAS testing and screening solution, the first developed and commercialized for the medical device industry. This offering provides insights to medical device manufacturers as they navigate the complex and evolving global regulations surrounding PFAS, ultimately contributing to medical device and patient safety.

play Anhören
share Teilen
feedback Feedback
copy Kopieren
newsletter
font_big Schrift vergrößern
Eurofins Scientific SA 66,59 $ Eurofins Scientific SA Chart -1,83%
Zugehörige Wertpapiere:

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251202959694/en/

Eurofins Medical Device Services is setting new standards with the industry's first GMP PFAS testing and advanced PFAS Risk Assessments for medical devices.

Eurofins Medical Device Services is setting new standards with the industry's first GMP PFAS testing and advanced PFAS Risk Assessments for medical devices.

Per- and polyfluoroalkyl substances, or PFAS, are a group of more than twenty thousand chemical compounds which are highly resistant to degradation and have been found to pose potential threats to human health and the environment. Implementing PFAS testing in the early development stages allows medical device manufacturers to prepare for potential regulatory updates and avoid future shutdowns, recalls, and liability issues, while further supporting their sustainability goals.

Eurofins Medical Device Services North America’s GMP PFAS testing and screening solution includes:

  • Combustion Ion Chromatography (CIC) for total organic fluorine screening in solids, liquids, and gases, to provide an initial assessment of PFAS levels.
  • Process mapping and supply chain audits, to identify contamination pathways.
  • Solvent extraction and direct combustion for flexible sample formats.
  • Extractables & Leachables (E&L) testing, toxicological risk assessments, and aging studies.
  • Stability and forced degradation studies, to identify PFAS breakdown products.

Eurofins Medical Device Services North America operates under ISO 17025 accreditation standards, and applies GMP best practices, ensuring sensitivity, specificity, and reproducibility even at trace levels.

Learn more at https://www.eurofins.com/medical-device/

About Eurofins Medical Device Services

Eurofins Medical Device Services offers comprehensive testing, consulting, and regulatory support for Class I, II, and III medical devices—including implants, instruments, single-use and combination products, and wearables.

With more than 40 years of experience, our global network of medical device testing laboratories and consultants provide strategic guidance from biological evaluation plans through commercialization, and specialize in international regulatory requirements, scientific trends, and tailored testing strategies.

Committed to global standards, Eurofins Medical Device Services designs and executes testing plans aligned with ISO, ASTM, ANSI, and AAMI standards, as well as custom methodologies. Our quality systems meet GMP and ISO 17025 requirements, helping clients accelerate market access with confidence.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251202959694/en/

Für dich aus unserer Redaktion zusammengestellt

Dein Kommentar zum Artikel im Forum

Jetzt anmelden und diskutieren Registrieren Login

Hinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte.


Weitere Artikel des Autors

Themen im Trend